AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 128 filers reported holding AMICUS THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is 0.95 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,343,507 | +26.1% | 521,670 | +30.2% | 0.00% | 0.0% |
| Q2 2023 | $5,031,134 | +67.9% | 400,568 | +48.2% | 0.00% | +100.0% |
| Q1 2023 | $2,997,040 | -57.4% | 270,247 | -53.1% | 0.00% | -66.7% |
| Q4 2022 | $7,037,246 | +267.1% | 576,351 | +213.9% | 0.00% | +200.0% |
| Q3 2022 | $1,917,000 | -36.3% | 183,591 | -34.5% | 0.00% | 0.0% |
| Q2 2022 | $3,011,000 | -38.0% | 280,330 | -45.3% | 0.00% | -50.0% |
| Q1 2022 | $4,853,000 | -11.7% | 512,442 | +7.7% | 0.00% | 0.0% |
| Q4 2021 | $5,497,000 | +75.6% | 475,870 | +45.2% | 0.00% | +100.0% |
| Q3 2021 | $3,131,000 | +126.9% | 327,846 | +129.0% | 0.00% | – |
| Q2 2021 | $1,380,000 | -57.5% | 143,190 | -56.4% | 0.00% | -100.0% |
| Q1 2021 | $3,245,000 | -47.3% | 328,500 | +23.1% | 0.00% | -50.0% |
| Q4 2020 | $6,162,000 | +145.9% | 266,898 | +50.4% | 0.00% | +100.0% |
| Q3 2020 | $2,506,000 | -9.1% | 177,460 | -2.9% | 0.00% | 0.0% |
| Q2 2020 | $2,756,000 | +71.0% | 182,791 | +4.8% | 0.00% | 0.0% |
| Q1 2020 | $1,612,000 | -44.7% | 174,464 | -41.7% | 0.00% | 0.0% |
| Q4 2019 | $2,917,000 | -57.5% | 299,438 | -65.0% | 0.00% | -66.7% |
| Q3 2019 | $6,863,000 | +86.6% | 855,842 | +190.4% | 0.00% | +200.0% |
| Q2 2019 | $3,677,000 | +72.2% | 294,691 | +87.7% | 0.00% | 0.0% |
| Q1 2019 | $2,135,000 | -73.9% | 156,988 | -81.6% | 0.00% | -75.0% |
| Q4 2018 | $8,172,000 | -55.8% | 853,029 | -44.2% | 0.00% | -42.9% |
| Q3 2018 | $18,484,000 | -30.6% | 1,528,815 | -10.3% | 0.01% | -36.4% |
| Q2 2018 | $26,637,000 | +14.3% | 1,705,271 | +10.0% | 0.01% | +10.0% |
| Q1 2018 | $23,308,000 | +594.5% | 1,549,739 | +564.5% | 0.01% | +900.0% |
| Q4 2017 | $3,356,000 | -27.9% | 233,202 | -24.4% | 0.00% | -50.0% |
| Q3 2017 | $4,654,000 | +214.7% | 308,623 | +110.2% | 0.00% | +100.0% |
| Q2 2017 | $1,479,000 | +98.8% | 146,852 | +40.7% | 0.00% | – |
| Q1 2017 | $744,000 | -42.9% | 104,391 | -60.2% | 0.00% | -100.0% |
| Q4 2016 | $1,304,000 | +22.7% | 262,258 | +82.5% | 0.00% | 0.0% |
| Q3 2016 | $1,063,000 | +10.2% | 143,713 | -18.6% | 0.00% | 0.0% |
| Q2 2016 | $965,000 | +29.4% | 176,580 | +100.0% | 0.00% | – |
| Q1 2016 | $746,000 | +19.9% | 88,282 | +37.7% | 0.00% | – |
| Q4 2015 | $622,000 | -0.3% | 64,127 | +43.7% | 0.00% | – |
| Q3 2015 | $624,000 | +42.1% | 44,641 | +43.8% | 0.00% | – |
| Q2 2015 | $439,000 | +96.9% | 31,044 | +51.4% | 0.00% | – |
| Q1 2015 | $223,000 | -75.8% | 20,500 | -81.5% | 0.00% | -100.0% |
| Q4 2014 | $920,000 | – | 110,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |